{
    "id": 24056,
    "fullName": "FRS2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FRS2 over exp indicates an over expression of the Frs2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10818,
        "geneSymbol": "FRS2",
        "terms": [
            "FRS2",
            "FRS1A",
            "FRS2A",
            "FRS2alpha",
            "SNT",
            "SNT-1",
            "SNT1"
        ]
    },
    "variant": "over exp",
    "createDate": "07/06/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7205,
            "approvalStatus": "Phase II",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical analysis of a Phase II trial, high Frs2 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027).",
            "molecularProfile": {
                "id": 24780,
                "profileName": "FRS2 over exp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6202,
                    "pubMedId": 25900027,
                    "title": "The impact of FGFR1 and FRS2\u03b1 expression on sorafenib treatment in metastatic renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25900027"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7203,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited proliferation liposarcoma cells with elevated FRS2 expression in culture (PMID: 23393200).",
            "molecularProfile": {
                "id": 24780,
                "profileName": "FRS2 over exp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3965,
                    "pubMedId": 23393200,
                    "title": "Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23393200"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24780,
            "profileName": "FRS2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}